Cannabis Stocks Shine On Primetime CNBC | Markets …

This article is published in collaboration with Scutify, where you can
find real-time markets and stock commentary from Robert Marcin, Cody Willard and others. Download the
Scutify iOS App, the Scutify Android App
or visit

Medical marijuana continues to gather major attention and yesterday, CNBC's Guy Adami announced that he is betting on cannabis-based medical company, GW Pharmaceuticals (GWPH).

Adami considers GW to not only be a play on medical marijuana but also a play on intellectual property. The company is a market disruptor and will be one of the biggest winners within the medical marijuana industry.

GW Pharma: An Industry Disruptor

GW Pharmaceutical is not a marijuana stock. It is a pharmaceutical company that already sells a cannabis-derived treatment for multiple sclerosis in 27 countries and it has by far, the most advanced pipeline of cannabis-derived products.

Not only does GW have the most advanced pipeline of products but it also has the most significant Wall Street coverage. Some of the largest banks in the world such as Goldman Sachs, Bank of America and Morgan Stanley, have Buy ratings on the firm. GW currently has an average price target of $154.95.

In late 2016, when Goldman Sachs initiated coverage on GW, it also placed a $390 acquisition price on the firm. Goldman Sachs was the first firm to issue a metric like this on GW and it is a testament to the value of GW's intellectual property.

A Favorable Outlook

We are favorable on GW Pharmaceuticals as it continues to execute on its product pipeline and work to create value for shareholders. Shares of GW Pharmaceuticals have come off its recent lows and are up more than 10% in the last month.

GW Pharmaceuticals has several major potential catalysts over the next two quarters and we continue to view the company as one of the best marijuana investment opportunities.

Our favorable view is based off: 1) GW Pharma has a deep pipeline of products in advanced stages of FDA testing, 2) Clinical data on the company's leading product candidate, Epidiolex has been very positive, 3) Management continues to execute and deliver on its promises, 4) GW has a strong balance sheet which will support the cost of clinical trials, and 5) Valuation is attractive as the average Wall Street price target implies more than 50% upside to current levels.

Stay up to date on the GreenRush by subscribing to Technical420...

Important Investor Disclosures

This report was authored by and is property of Technical420. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by Technical420 regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only

This article was written by Mark Maulden for on .

This article published in collaboration with Scutify, the best app
for traders and investors. Download the Scutify iOS App, the
Scutify Android App or visit

Receive Updates

No spam guarantee.

Leave a Reply

Your email address will not be published. Required fields are marked *

Skip to toolbar